Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

Journal of Clinical Oncology

Volumn 19, Issue 19, 2001, Pages 3967-3975

  Clarke Pearson, D L ^a   Van Le, L ^a   Iveson, T ^a   Whitney, C W ^a   Hanjani, P ^a   Kristensen, G ^a   Malfetano, J H ^a   Beckman, R A ^a   Ross, G A ^a   Lane, S R ^a   DeWitte, M H ^a   Fields, S Z ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EVALUATION; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0035478878     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.19.3967     Document Type: Article

References (25)

1. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
4. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
5. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
6. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
7. Final analysis of a phase III, randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group
8. Oral topotecan: Bioavailability and effect of food co-administration
9. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan
10. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours
11. Summary of symposium: Biology and therapy of ovarian cancer
12. Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
13. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
14. Chemotherapy of advanced ovarian cancer
15. Experience with independent radiological review during a topotecan trial in ovarian cancer
16. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
17. A multicentre, randomized, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma
18. A multicenter randomized phase II study of oral topotecan versus iv topotecan for second line therapy in sensitive patients with small cell lung cancer
19. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
20. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
21. Topotecan has substantial antitumor activity as first-line salvage therapy in platinumsensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study